Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683624 | 0.91 | RXFP1 (0.58) | LMNASMN1; SMN2POLBRXFP1ALDH1A1 | |
| Water SCHEMBL10753533 | 0.90 | RXFP1 (0.58) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL684332 | 0.88 | MAPK1 (0.55) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL684335 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL683975 | 0.83 | LMNA (0.65) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL683960 | 0.82 | ALDH1A1 (0.58) | LMNASMN1; SMN2POLBRXFP1ALDH1A1 | |
| SCHEMBL682806 | 0.81 | LMNA (0.62) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL683617 | 0.79 | CHRM2 (0.51) | LMNAPOLBMAPK1RXFP1ALDH1A1 | |
| SCHEMBL10573674 | 0.79 | LMNA (0.59) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| Flufylline SCHEMBL684324 | 0.79 | HTR2A (0.60) | LMNARXFP1ALDH1A1CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LMNA 2155/4885SMN1; SMN2 907/4885POLB 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.